MaxCyte, Inc.
HealthcareNASDAQ:MXCT · NASDAQ Global Select
+$0.02 today
Vol 0.49M · Avg 0.96M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-26.0%
avg -31.9%
ROIC
-23.9%
avg -28.6%
ROA
-22.0%
avg -22.3%
Analysis
ROA is currently the strongest return metric at -22.0% versus its period average of -22.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Maher Masoud | President, Chief Executive Officer & Executive Director | $919,082.00 | — | 50 | $475,000.00 | 0.44% |
Parmeet Ahuja | Chief Financial Officer | $700,557.00 | — | 57 | $187,500.00 | 0.18% |
Ana-Paula Martins Fernandes | Senior Vice President of Global Sales | — | — | — | — | — |
Jill Mayer | Senior Vice President of Human Resources | — | — | — | — | — |
Jay Gelfman | Chief Operations Officer | — | — | — | — | — |
Jack Horgan | Senior Vice President of Corporate Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$480,175.00
Sells
2
$30,643.37
Net Sentiment
+$449,531.63
Net buying
Most Active
Swirsky Douglas J
2 transactions
Analysis
Insiders reported 5 buys worth $480,175.00 and 2 sells worth $30,643.37 over the last 12 months. That adds up to net buying of $449,531.63. Swirsky Douglas J was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +21.7% | +15.7% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +21.7% over three years. Forward estimates point to Revenue at +15.7% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Prenetics Global Limited
NASDAQ:PRE
$367.72M
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
Perspective Therapeutics, Inc.
AMEX:CATX
$227.89M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$142.92M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Owlet, Inc.
NYSE:OWLT
$84.14M
LENSAR, Inc.
NASDAQ:LNSR
$70.45M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Who manages MXCT?
MaxCyte, Inc. (MXCT) lists 6 active executives. The top listed executive is Maher Masoud, President, Chief Executive Officer & Executive Director.
Are MXCT insiders buying or selling?
Recent insider activity shows net buying of $7.61M.
Explore More
Continue the stock analysis
Jump to another research area for this company.